New hay fever pill will retrain the immune system
The immunotherapy drug aims to treat the root cause of symptoms by retraining the immune system to tolerate tree pollen over three years of daily use.
Betula verrucosa, sold under the brand name Itulazax 12 SQ-Bet and made by ALK-Abello, is a tablet that contains birch pollen extract.
It has been recommended by the National Institute for Health and Care Excellence (Nice) to be an option the NHS for around 27,000 people whose hay fever symptoms persist even after taking antihistamines or using nasal sprays.
About 13 million people in the UK have hay fever during the spring and summer months, and about one in four sufferers are allergic to tree pollen.
Severe tree pollen allergies can cause debilitating symptoms for some people during the spring and summer months, including fatigue, breathing difficulties, inflamed sinuses, itchy, watery eyes and changes in vision.
Trials show the tablet can significantly reduce the symptoms of severe hay fever by changing how the body responds to allergens.
Could benefit 27,000 people
The immunotherapy works by gradually increasing the body's tolerance to tree pollen through controlled daily exposure to small amounts of pollen.
Before being given the tablets, patients will require a skin prick or blood tests to confirm an allergy to birch tree pollen.
Nice estimates that about 27,000 people in England are expected to benefit from the recommendation.
Helen Knight, director of medicines evaluation at Nice, said: 'This treatment will help improve people's quality of life.
'Severe tree pollen allergies trap people indoors during beautiful weather and disrupt their work, education and family life.
'The daily tablet offers genuine long-term relief rather than just managing symptoms.'
According to Allergy UK, birch pollen allergy is estimated to affect about a quarter of hay fever sufferers.
Amena Warner, head of clinical services at Allergy UK, said: 'Many people don't realise how awful it is having an itchy, runny nose, sneezing episodes or itchy, irritated eyes in the pollen season.
'We frequently hear from people who avoid time outdoors, keep doors and windows shut, check pollen counts and try and minimise any exposure, which takes a significant toll on their physical and emotional wellbeing.
'Nice's recommendation is so important because it provides a genuine opportunity for people to manage the root cause of their pollen allergy, offering the chance to break free from this burden and enjoy a better quality of life.'
Emil Stage Olsen, ALK-Abello's general manager for the UK and Ireland, added: 'We welcome this positive Nice recommendation, which is another meaningful advancement for the UK allergy community.
'Our focus is now on working closely with the NHS to ensure eligible patients can benefit from this first-in-class immunotherapy.'
The NHS in England will provide the treatment within three months of Nice publishing its final guidance.
Prof Meghana Pandit, co-medical director at NHS England, welcomed the announcement.
She said: 'This innovative treatment, which will soon be rolled out on the NHS, enables patients to build up tolerance to birch tree pollen within their immune system, rather than just treating the symptoms – and we hope this will give many a new lease of life, allowing people to spend time enjoying being outside, without the discomfort allergies can bring.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Air ambulance called to assist injured hiker in the Lake District
Wasdale Mountain Rescue Team (MRT) attended a callout following reports of an injured hiker. The team were alerted by Cumbria Police e about a young walker who had fallen, hitting her head and resulting in a large lump and cut. The callout occurred on Over Beck, Yewbarrow, and saw an air ambulance attend the scene to help the hiker. A member of Wasdale MRT said: "The team was quickly mobilised, with Helimed 58 also responding immediately. "As usual, aviation fuel was quicker than foot power, and fortunately the helicopter this time was able to land very close to the scene. "After assessment, the walker was airlifted to hospital for further care, with team members meeting up with the rest of the walking party on their way out of the valley." The callout lasted three hours and 12 minutes, and took place on July 24. A member of Wasdale MRT said: "We hope the walker makes a full recovery and is back on the fells soon."
Yahoo
2 hours ago
- Yahoo
LIfT BioSciences announces grant of €12 million from Ireland's Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT's IMAN therapy
Galway, London, 29 July 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland's Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026. The €12 million grant, the largest grant awarded by the DTIF to date, was awarded to a consortium LIfT formed with the University of Galway, renowned for their expertise in cell therapy development, innovation, and clinical trials and Hooke Bio, pioneers of a novel immuno-analytics platform designed to enhance therapy response rates, as part of the Company's grant application process. The funding will be used to conduct an investigator initiated clinical trial designed to test the feasibility and safety of IMAN therapy administered to patients with metastatic cervical cancer or head and neck cancer who have exhausted all standard treatment options, including checkpoint inhibitors. Alex Blyth, Chief Executive Officer of LIfT Biosciences, said: 'The grant awarded from DTIF is a significant milestone for LIfT as we expand our presence in Ireland and advance toward closing the second round of our Series A financing. By combining LIfT's innovative immunotherapy platform with the University of Galway's deep expertise in oncology, patient care, and advanced manufacturing, and Hooke Bio's analytical expertise, we are enhancing our clinical-stage research and accelerating the path to delivering IMANs to patients. The majority of this grant will support CMC manufacturing and the clinical trial itself, positioning LIfT at the forefront of next-generation cancer immunotherapies.' Commenting on the award, Peter Burke, Minister for Enterprise, Tourism and Employment, said that 'The Government established the Disruptive Technologies Innovation Fund to invest in technologies that demonstrate true innovation and with the potential to address critical national and societal challenges. We want to fund projects that will make a real difference to people's lives. The N-LIfT project has come through a rigorous evaluation process and the level of funding awarded reflects its potential to be a game-changer in cancer therapy. I'm excited to see the impact it will deliver.' The trial will test progressively higher IMAN doses in sequential patient cohorts to determine the biologically active dose. It will then be expanded to additional patients who will be infused with IMANs at the previously determined recommended dose in combination with checkpoint inhibitor therapy. The results of this evaluation will help bring this promising technology to cancer patients faster and enable LIfT to attract additional investment into Ireland for its ongoing clinical and manufacturing programme in Galway. Dr Michael McCarthy, Consultant Medical Oncologist and Principal Investigator at University Hospital Galway added: 'Cancer remains one of the most complex and dynamic diseases. IMANs have the potential to overcome key limitations of current cancer treatments by activating both the innate and adaptive branches of the immune system. This dual stimulation enables a comprehensive anti-tumour response, representing a transformative advancement in cancer therapy. We are pleased to receive this grant in collaboration with LIfT and Hooke Bio, and we look forward to accelerating the clinical development of this groundbreaking immunotherapy.' Professor Sean Hynes, Consultant Histopathologist and Translational Cancer Researcher from the School of Medicine and Lead Academic on the award commented: 'In partnership with LIfT Biosciences and Hooke Bio, we are very excited about the University of Galway and Galway University Hospital being at the forefront of delivering on new oncological cellular therapies by using neutrophils, the body's own first responders, in the fight against cancer and ensuring patients in the West of Ireland have access to such cutting edge treatments.' Mark Lyons, Ph.D., CEO at Hooke Bio added: 'We're very excited to be able to employ our Mera body on a plate platform to support the development of LIfT's immuno-oncology therapeutic. This project highlights the strength of the Irish clinical research eco system and the power of collaboration.' DTIF is a €500 million challenge-based fund established under Project Ireland 2040. It is one of four funds set up under the National Development Plan (NDP) 2018-2027. It is managed by the Department of Enterprise, Trade and Employment and administered by Enterprise Ireland. The DTIF fund is for clients of Enterprise Ireland, Údarás na Gaeltachta, IDA Ireland and research performing organisations in Ireland that are collaborating on industrial research and / or experimental development in highly innovative projects. LIfT, registered as Eolaíocht Bhitheach LIfT Teoranta, has a base in An Spidéal, Co. Galway at (gteic@An Spidéal) and, as an Údarás na Gaeltachta client, has been supported by them to create employment in the Gaeltacht. About LIfT BioSciencesLIfT BioSciences is a UK and Ireland-based biotech pioneering a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by restoring immune competence. Its Immuno-Modulatory Alpha Neutrophils (IMANs) recognise and destroy cancer cells through advanced threat pattern recognition in a non-antigen-specific manner. Clinical studies show that this class of neutrophils can prevent tumour escape—responsible for over 90% of cancer-related deaths—by delivering a durable, total immune response and lasting immunity. LIfT's patented N-LIfT platform is derived from exceptional donor stem cells cultured in a proprietary enhancement media, enabling scalable and potent cell production. The company is also advancing iPSC technology and genetic engineering to create next-generation IMAN therapies with pharma partners to achieve cost-effective, long-term remission for cancer patients and beyond. LIfT is currently completing its 2nd close on its Series A Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@
Yahoo
2 hours ago
- Yahoo
What is liver cancer? Expert explains causes, symptoms and how to treat it
The number of liver cancer cases is expected to double by 2050, with rising obesity rates partly responsible, researchers have warned. Experts predict that the share of liver cancer cases linked to obesity will grow from 5 per cent to 11 per cent, urging stronger efforts to prevent avoidable cases. New projections from a Lancet Commission on Liver Cancer report estimate that global liver cancer cases will increase from 0.87 million in 2022 to 1.52 million by 2050. Many adults remain unaware of the risk factors for liver cancer, so we spoke to a medical adviser at the British Liver Trust, Anya Adair, who is also a consultant transplant and hepatobiliary surgeon at Edinburgh Royal Infirmary. She shared some key insights into the main causes, symptoms and treatments of this serious disease. What is liver cancer and what causes it? 'Cancer that develops within the liver is primary liver cancer, but when cancers arise from somewhere else in the body and then spread to the liver, that is secondary cancer,' explains Adair. How serious liver cancer is depends on the patient's general health, where the cancer is in the liver, how big it is, if it has spread and if it's primary or secondary cancer. according to the NHS website. 'Liver cancer can develop within the liver tissue, which is called primary hepatocellular carcinoma (HCC),' explains Adair. HCC occurs when cells called hepatocytes start to multiply and grow more than they should, according to the Liver Cancer Trust, part of the British Liver Trust. 'However, cancer can also develop within the bile duct systems in the liver, which is called cholangiocarcinoma,' adds Adair. Around three out of four cancers that start in the liver are HCC, according to the Liver Cancer Trust, which typically develops in livers that are already scarred and damaged, a condition known as cirrhosis. 'You could have a scarred cirrhotic liver due to alcohol consumption, but it can also be because of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), previous known as Nonalcoholic Fatty Liver Disease,' highlights Adair. Both autoimmune hepatitis and primary biliary cholangitis (both of which are autoimmune liver diseases) can also lead to a scarred cirrhotic liver if left untreated, she adds. What are some common symptoms? 'The problem with HCC is that it often doesn't present with any symptoms at all,' says Adair. 'So, it is usually found incidentally on a scan that has been done for something else if the person didn't know that they had a scarred liver.' HCC is also sometimes flagged up during a routine ultrasound that people who know they have a cirrhotic liver tend to have. 'Sometimes people with a cirrhotic liver are in surveillance and have ultrasounds every six months because the risk is higher, and during the scan a new swelling or shadow in the liver is picked up,' notes Adair. Although liver cancer is often silent in the beginning stages, Adair highlights that once it becomes more advanced, patients may start to develop symptoms such as jaundice, unexplained weight loss, tiredness and/or nausea. 'Anyone who develops jaundice should seek urgent medical attention, and unexplained weight loss in particular is also an alarm bell,' says Adair. How is it diagnosed? 'Liver cancer is usually spotted on an ultrasound initially, which is then followed by CT and MRI scans,' says Adair. 'So, it's usually a radiological diagnosis, and in some situations you need a biopsy for confirmation.' What are the treatment options? 'There are a lot of treatment options depending on how bad your liver disease is, how many cancers in the liver you have, how big they are and what your general fitness is,' explains Adair. There are several curative options, including surgery. 'If the cancer is picked up relatively early, and you are within transplant criteria, then a liver transplant is a curative option,' says Adair. 'If the liver is working well and there is only one area of cancer, then patients could think about having a liver resection, where you take part of the liver away. 'In addition, patients who have a single lesion that is below three centimetres can opt for ablation.' This minimally invasive procedure uses heat or extreme cold to destroy the targeted tissue, according Liver Cancer UK. There are also other treatment options that help hold the liver cancer tumour at bay or are a bridge to further treatment, such as chemoembolisation (combining chemotherapy with a method to block blood flow to the tumour) or local radiation.
